C4 Therapeutics Q1 net loss narrows to $28.4M; cash $299M into 2027; Biogen milestone $8M, Merck deal up to $740M

C4 Therapeutics, Inc.

2023-Q1 EPS reported -$0.41 revenue$3,039,000

Revenue $3.0M (down from $3.8M YoY); net loss per share $0.41 vs $0.71.
Cash $299.2M as of Mar 31; expected runway into 2027.
Earned $8M from Biogen; Merck KGaA collaboration with $16M upfront and up to $740M milestones.
Phase 1 trials for cemsidomide (MM/NHL) and CFT1946 (solid tumors) progressing; data expected 2H 2024.
Appointed Dan Powers as SVP clinical development.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

C4 Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $3.0 million.

Period: first quarter ended March 31, 2024
Revenue: $3.0 million
Result: reported results

Exact text from the filing

Total revenue for the first quarter of 2024 was $3.0 million

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-021367

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.